Claire’s Place Foundation Launches First East Coast Glow Ride for Cystic Fibrosis
August 08, 2023 11:50 ET
|
Claire's Place Foundation
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is excited to...
Claire’s Place Foundation Announces 9th Annual Glow Ride for Cystic Fibrosis
July 13, 2023 08:00 ET
|
Claire's Place Foundation
Los Angeles, CA, July 13, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
July 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
July 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
June 30, 2023 01:15 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
June 28, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Strengthens Intellectual Property Estate
June 27, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)
June 15, 2023 11:31 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
June 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
Two-thirds of patients have completed study, final patients being dosedTop line data read-out on track for July 2023 BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc....
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
June 07, 2023 01:15 ET
|
Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...